Altered T Cell Migratory Capacity in the Progression from Barrett Oesophagus to Oesophageal Adenocarcinoma.
Barrett Oesophagus
Chemokines
Immunotherapy
Oesophageal cancer
T cells
Journal
Cancer microenvironment : official journal of the International Cancer Microenvironment Society
ISSN: 1875-2292
Titre abrégé: Cancer Microenviron
Pays: Netherlands
ID NLM: 101322634
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
20
12
2018
accepted:
07
02
2019
pubmed:
6
3
2019
medline:
6
3
2019
entrez:
6
3
2019
Statut:
ppublish
Résumé
Oesophageal adenocarcinoma (OAC) is an inflammation-driven cancer with poor prognosis and incidence is increasing rapidly. OAC arises from gastro-oesophageal reflux disease (GORD) and reflux-induced Barrett oesophagus (BO). The role of T cells in this disease progression is not yet fully understood. We have previously demonstrated higher proportions of pro-tumour Th2 cells in BO tissue, implicating them in its pathogenesis. While a Th2 immune profile is thought to underlie the metaplastic transformation in BO and promote OAC development, our studies suggest that the abundance of Th2 cells in BO tissue is likely to occur through altered T cell recruitment. This study examined the chemokine networks governing T cell migration to oesophageal tissue during disease progression. Here, we have identified that circulating T cells in OAC patients, exhibit impaired migratory capacity with decreased frequencies of Th1-associated CXCR3
Identifiants
pubmed: 30834503
doi: 10.1007/s12307-019-00220-6
pii: 10.1007/s12307-019-00220-6
pmc: PMC6529503
doi:
Types de publication
Journal Article
Langues
eng
Pagination
57-66Subventions
Organisme : Health Research Board (Ireland)
ID : Health Research Award HRA_POR/2012/18
Références
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13812-7
pubmed: 11095721
Blood. 2002 Jun 15;99(12):4283-97
pubmed: 12036854
Am J Gastroenterol. 2003 Mar;98(3):551-6
pubmed: 12650786
Blood. 2003 Oct 15;102(8):2724-7
pubmed: 12816871
Gut. 2004 Aug;53(8):1070-4
pubmed: 15247170
Clin Cancer Res. 2004 Nov 15;10(22):7529-39
pubmed: 15569983
Int J Cancer. 2006 Apr 15;118(8):1909-14
pubmed: 16287061
Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943
pubmed: 16928254
Best Pract Res Clin Gastroenterol. 2008;22(4):661-9
pubmed: 18656823
Clin Cancer Res. 2010 Mar 1;16(5):1520-31
pubmed: 20160057
Biol Pharm Bull. 2010;33(6):1067-9
pubmed: 20522980
Exp Cell Res. 2011 Mar 10;317(5):620-31
pubmed: 21376175
Cancer Sci. 2011 Jul;102(7):1264-71
pubmed: 21443538
Br J Surg. 2011 Jul;98(7):964-74
pubmed: 21520028
Curr Probl Dermatol. 2011;41:80-92
pubmed: 21576949
Med Oncol. 2014 Apr;31(4):882
pubmed: 24554520
Am J Physiol Gastrointest Liver Physiol. 2014 Apr 15;306(8):G641-9
pubmed: 24578343
Expert Opin Drug Discov. 2014 May;9(5):467-83
pubmed: 24641500
PLoS One. 2014 Jun 30;9(6):e101137
pubmed: 24979261
Eur J Pharmacol. 2015 Sep 15;763(Pt B):169-77
pubmed: 25981299
Cancer Lett. 2016 Jan 1;370(1):117-24
pubmed: 26519754
World J Gastroenterol. 2016 Jan 14;22(2):833-41
pubmed: 26811629
Immunol Cell Biol. 2016 Jul;94(6):531-7
pubmed: 27046081
Br J Cancer. 2016 Jun 14;114(12):1343-51
pubmed: 27149649
Oncoimmunology. 2016 May 24;5(8):e1189052
pubmed: 27622061
Oncotarget. 2017 Sep 28;8(52):89998-90012
pubmed: 29163806
Front Immunol. 2018 Aug 13;9:1867
pubmed: 30150990
Science. 1995 Dec 15;270(5243):1811-5
pubmed: 8525373
J Exp Med. 1998 Mar 16;187(6):875-83
pubmed: 9500790
Blood. 1998 Dec 1;92(11):4036-9
pubmed: 9834206
Immunol Today. 1998 Dec;19(12):568-74
pubmed: 9864948